Your shopping cart is currently empty

Telotristat ethyl (LX1606) is a orally-delivered inhibitor of tryptophan hydroxylase that reduces serotonin production.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $34 | In Stock | In Stock | |
| 5 mg | $77 | In Stock | In Stock | |
| 10 mg | $123 | In Stock | In Stock | |
| 25 mg | $232 | In Stock | In Stock | |
| 50 mg | $376 | In Stock | In Stock | |
| 100 mg | $566 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $98 | In Stock | In Stock |
| Description | Telotristat ethyl (LX1606) is a orally-delivered inhibitor of tryptophan hydroxylase that reduces serotonin production. |
| In vivo | Telotristat ethyl, at a dosage of 200 mg/kg administered orally once daily, has been shown to protect against inflammatory bowel disease (IBD) in mice, as evidenced by histopathology evaluations[1] and by alleviating the severity of colitis induced by trinitrobenzene sulfonic acid (TNBS)[2]. At various dosages (15, 50, 150, 300 mg/kg), Telotristat ethyl effectively reduces serotonin (5-HT) levels in the jejunum, though it does not affect serotonin levels in the brain or impact the enteric neuronal serotonin nor constitutive gastrointestinal motility at a 200 mg/kg dosage. Additionally, it prevents the TNBS-induced increase in blood neutrophil counts, highlighting its significant protective role in a mouse model of IBD, without altering serotonin content within the brain, even at differing concentrations (15, 50, 150, 300 mg/kg, administered orally once daily). |
| Synonyms | LX1606 |
| Molecular Weight | 574.98 |
| Formula | C27H26ClF3N6O3 |
| Cas No. | 1033805-22-9 |
| Smiles | CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1 |
| Relative Density. | 1.42 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 115 mg/mL (200.01 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (5.74 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.